Reports
Global Active Pharmaceutical Ingredient (API) Market Share, Size, Analysis: By Molecule: Small Molecule, Large Molecule; By Type: Innovative Active Pharmaceutical Ingredients, Others; By Indications; By Type of Manufacturers; By Potency; By Therapeutic Applications; By Distribution Channel; Regional Analysis; Supplier Landscape; 2023-2031
Global Active Pharmaceutical Ingredients Market Outlook
The global active pharmaceutical ingredients market reached a value of about USD 185 billion in 2020. The market is further expected to grow at a CAGR of about 5.5% in the forecast period between 2021 and 2026 to reach USD 255 billion by 2026.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The active pharmaceutical ingredients market, catalysed by lower prices, has slowly shifted from the historical leaders of western nations to manufacturers in developing countries like China and India. For a range of large and small suppliers, the global active pharmaceutical ingredients market is highly competitive. Companies involved in its production typically specialise in their manufacturing processes and plan their production on the basis of a combination of internal competencies and business possibilities.
Market Segmentation
Active pharmaceutical component (API) refers to the biologically active ingredient of a medicine. Generally, a medicine consists of several components, where the primary component is the API. Other additives are typically known as excipients. Often a drug may include many APIs, and its effect on a patient is dependent on the prescription dosage and may differ from person to person. In combination therapy, two or more active drugs are used to treat various symptoms in multiple ways.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
On the basis of drug type, the market can be divided into the following:
- Innovative
- Generic
Based on the type of manufacturer, the industry is further segmented into:
- Captive
- Merchant API
Merchant API manufacturers can be further divided into innovative merchant API manufacturers and generic merchant API manufacturers. Based on the type of synthesis, the market can be divided into synthetic and biotech active pharmaceutical ingredients.
On the basis of type, the synthetic active pharmaceutical ingredients can be segmented into innovative synthetic APIs and generic synthetic APIs.
Biotech active pharmaceutical ingredients can be further categorised on the basis of type, product, and expression system. Based on type, the market can be divided as follows:
- Innovative Biotech APIs
- Biosimilars
On the basis of the product, the industry is segmented into the following:
- Monoclonal Antibodies
- Vaccines
- Cytokines
- Fusion Proteins
- Therapeutic Enzymes
- Blood Factors
Based on expression system, the biotech active pharmaceutical ingredients segment can be divided as follows:
- Mammalian Expression Systems
- Microbial Expression Systems
- Yeast Expression Systems
- Transgenic Animal Systems
- Others
Based on therapeutic application, the market can be segmented as follows:
- Oncology
- Cardiovascular and Respiratory Disorders
- Diabetes
- Central Nervous System Disorders
- Neurological Disorders
- Others
The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Analysis
The rising proliferation of chronic conditions has led to a rise in drug demand and, thus, to an increase in the global active pharmaceutical ingredients market. In addition, some manufacturers are investing in R&D activities in order to offer higher quality, low-cost APIs, which can help cure illnesses outside the reach of small molecular medicinal products. Therefore, pharmaceutical firms move their manufacturing facilities to developing economies and outsource their operations to maximize production and increase input costs. In addition, there is likely to be a substantial increase in the market for generic APIs as a result of a loss of patent rights for blockbuster drugs worth several billion dollars over the next few years.
The growing number of blockbusters patent expiries is among the key drivers of this industry and provides a substantial chance to generic active pharmaceutical ingredients. In addition, the demand for active pharmaceutical ingredients for bio-based substances has been rising. The global biologics market is currently showing a strong growth, which is catalysed by its high power and ability to treat diseases other than small molecule medicines. This has led to a high demand for APIs and their biosimilar versions of marketed biological drugs. The ageing population, higher expenditure on healthcare, and increased prevalence of lifestyle diseases are the other factors that are catalysing the market.
Competitive Landscape
The report gives a detailed analysis of the following key players in the global active pharmaceutical ingredients market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
- Pfizer, Inc.
- Novartis International AG
- Teva Pharmaceutical Industries Ltd.
- Abbvie Inc
- Others
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2016-2022 |
| Forecast Period | 2023-2031 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Molecule |
|
| Breakup by Type |
|
| Breakup by Indications |
|
| Breakup by Type of Manufacturers |
|
| Breakup by Potency |
|
| Breakup by Therapeutic Applications |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Active Pharmaceutical Ingredient (API) Market Overview
3.1 Global Active Pharmaceutical Ingredient (API) Market Historical Value (2016-2022)
3.2 Global Active Pharmaceutical Ingredient (API) Market Forecast Value (2023-2031)
4 Global Active Pharmaceutical Ingredient (API) Market Landscape
4.1 Global Active Pharmaceutical Ingredient (API) Company Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Active Pharmaceutical Ingredient (API) Product Landscape
4.2.1 Analysis by Molecule Type
4.2.2 Analysis by Type
4.2.3 Analysis by Indications
4.2.4 Analysis by Types of Manufactures
4.2.5 Analysis by Potency
4.2.6 Analysis by Therapeutic Applications
4.2.7 Analysis by Distribution Channel
5 Global Active Pharmaceutical Ingredient (API) Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Active Pharmaceutical Ingredient (API) Market Segmentation
6.1 Global Active Pharmaceutical Ingredient (API) Market by Molecule
6.1.1 Market Overview
6.1.2 Small Molecule
6.1.3 Large Molecule
6.2 Global Active Pharmaceutical Ingredient (API) Market by Type
6.2.1 Market Overview
6.2.2 Innovative Active Pharmaceutical Ingredients
6.2.3 Generic Active Pharmaceutical Ingredients
6.3 Global Active Pharmaceutical Ingredient (API) Market by Indications
6.3.1 Market Overview
6.3.2 Acetaminophen
6.3.3 Artemisinin
6.3.4 Saxagliptin
6.3.5 Sodium Chloride
6.3.6 Ibuprofen Losartan Potassium
6.3.7 Enoxaparin Sodium
6.3.8 Rufinamide
6.3.9 Naproxen
6.3.10 Tamoxifen
6.3.11 Others
6.4 Global Active Pharmaceutical Ingredient (API) Market by Type of Manufacturers
6.4.1 Market Overview
6.4.2 Captive API Manufacturer
6.4.3 Merchant API Manufacturer
6.5 Global Active Pharmaceutical Ingredient (API) Market by Potency
6.5.1 Market Overview
6.5.2 Low to Moderate
6.5.3 Potent to Highly Potent
6.6 Global Active Pharmaceutical Ingredient (API) Market by Therapeutic Applications
6.6.1 Market Overview
6.6.2 Cardiology
6.6.3 CNS & neurology
6.6.4 Oncology
6.6.5 Orthopedic
6.6.6 Endocrinology
6.6.7 Pulmonology
6.6.8 Gastroenterology
6.6.9 Nephrology
6.6.10 Ophthalmology
6.6.11 Other
6.7 Global Active Pharmaceutical Ingredient (API) Market by Distribution Channel
6.7.1 Overview
6.7.2 Direct Tenders
6.7.3 Retail Slaes
6.7.4 Online Pharmacies
6.7.5 Others
6.8 Global Active Pharmaceutical Ingredient (API) Market by Region
6.8.1 Market Overview
6.8.2 North America
6.8.3 Europe
6.8.4 Asia Pacific
6.8.5 Latin America
6.8.6 Middle East and Africa
7 North America Active Pharmaceutical Ingredient (API) Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Active Pharmaceutical Ingredient (API) Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Active Pharmaceutical Ingredient (API) Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Active Pharmaceutical Ingredient (API) Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Active Pharmaceutical Ingredient (API) Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 AstraZeneca
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Bristol-Myers Squibb
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Eli Lilly and Company
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 F. Hoffmann-La Roche AG
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 GlaxoSmithKline
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Johnson & Johnson
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Merck & Co., Inc.
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Novartis International AG
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Pfizer Inc.
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Sanofi
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Takeda Pharmaceutical Company Limited
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Celgene Corporation
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 Amgen Inc.
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
17.14 Gilead Sciences, Inc.
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.14.5 Certifications
17.15 Bayer AG
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisitions
17.15.5 Certifications
17.16 AbbVie Inc.
17.16.1 Financial Analysis
17.16.2 Product Portfolio
17.16.3 Demographic Reach and Achievements
17.16.4 Mergers and Acquisitions
17.16.5 Certifications
17.17 Regeneron Pharmaceuticals, Inc.
17.17.1 Financial Analysis
17.17.2 Product Portfolio
17.17.3 Demographic Reach and Achievements
17.17.4 Mergers and Acquisitions
17.17.5 Certifications
17.18 Genentech
17.18.1 Financial Analysis
17.18.2 Product Portfolio
17.18.3 Demographic Reach and Achievements
17.18.4 Mergers and Acquisitions
17.18.5 Certifications
17.19 Seattle Genetics, Inc.
17.19.1 Financial Analysis
17.19.2 Product Portfolio
17.19.3 Demographic Reach and Achievements
17.19.4 Mergers and Acquisitions
17.19.5 Certifications
17.20 Aimmune Therapeutics
17.20.1 Financial Analysis
17.20.2 Product Portfolio
17.20.3 Demographic Reach and Achievements
17.20.4 Mergers and Acquisitions
17.20.5 Certifications
18 Global Active Pharmaceutical Ingredient (API) Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
In 2020, the global active pharmaceutical ingredients market attained a value of nearly USD 185 billion.
In the forecast period of 2023-2028, the market is expected to grow at a CAGR of 5.5%.
By 2026, the market is expected to attain a value of USD 255 billion.
The major drivers of the industry, such as the rising demand from the emerging nations, growing biologics market, increasing healthcare expenditure, and the rising R&D investments, are aiding the growth of the market.
The key trend guiding the growth of the market includes the upcoming expiry of blockbuster drugs patents, which provides a significant growth potential for generic active pharmaceutical ingredients.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The major drug types in the industry are innovative and generic active pharmaceutical ingredients.
The significant types of manufacturers of the product in the industry are captive and merchant API.
The leading types of synthesis of the product in the industry are synthetic and biotech active pharmaceutical ingredients.
The significant therapeutic applications of the product in the industry are oncology, cardiovascular and respiratory disorders, diabetes, central nervous system disorders, and neurological disorders, among others.
The major players in the industry are Novartis International AG, Teva Pharmaceutical Industries Ltd., and Abbvie Inc, among others.
Analyst Review
The global active pharmaceutical ingredients market attained a value of USD 185 billion in 2020, driven by the growing expenditure on healthcare. Aided by rising demand for generic APIs, the market is expected to witness a further growth in the forecast period of 2023-2028, growing at a CAGR of 5.5%. The market is projected to reach USD 255 billion by 2026.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on its drug types, the market can be segmented into innovative and generic active pharmaceutical ingredients. On the basis of types of manufacturers, the market can be divided into captive and merchant API. By types of synthesis, the industry is bifurcated into synthetic and biotech active pharmaceutical ingredients. Oncology, cardiovascular and respiratory disorders, diabetes, central nervous system disorders, and neurological disorders, among others, are the major therapeutic applications of the product in the industry. The major regional markets for active pharmaceutical ingredients are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific. The key players in the above market include Novartis International AG, Teva Pharmaceutical Industries Ltd., and Abbvie Inc, among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$3499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$5999-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$7999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$9999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
NEWSLETTER